Multiple or Single Endocrine Abnormalities Associated With Immune Checkpoint Inhibitors
The development of multiple endocrine abnormalities in patients treated with ICIs is associated with improved survival compared with that of patients with a single abnormality.
Authors
- Tomoya Myojin (ORCID: https://orcid.org/0000-0002-3820-6157)
- Tatsuya Noda (ORCID: https://orcid.org/0000-0002-3652-7547)
- Yutaka Takahashi (ORCID: https://orcid.org/0000-0002-1337-9246)
- Tomoaki Imamura (ORCID: https://orcid.org/0000-0003-1981-9959)
- Fumika Kamitani (ORCID: https://orcid.org/0000-0002-2838-7986)
- Yuichi Nishioka (ORCID: https://orcid.org/0000-0002-1956-3925)
- Hiroki Nakajima (ORCID: https://orcid.org/0000-0002-5899-0903)
- Sadanori Okada (ORCID: https://orcid.org/0000-0002-3097-8152)
- Yukako Kurematsu
Institutions
- Nara Medical University (JP)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1210/clinem/dgaf347
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Japan Association for Diabetes Education and Care
- Japan Society for the Promotion of Science London
- Novo Nordisk
- Japan Society for the Promotion of Science
- Daiichi Sankyo Europe